Replies to post #48789 on Biotech Values

[DewDiligence]

> COLY – I was listening very carefully on today's CC for Bratzler's answer regarding whether the '676 arm did worse than the control arms. "No indication of that." That could mean the DSMB just didn't say… Would the DSMB stop these PFE trials this early just because there was no difference? Any opinions on the likelihood some side effect or worsening survival in the 676 group was seen?<

Almost certainly, the 676 arm did worse than the control arm, and worse probably means toxicity that was additive to what is seen with standard chemo. The tip-off is that the phase-2 trial with 676+Tarceva—the only 676 trial that does not include chemo—has not (yet) been terminated. Regards, Dew